BioSante Pharmaceuticals to Present at The Arch Investment Conference
LINCOLNSHIRE, Illinois (September 4, 2007) – BioSante Pharmaceuticals (AMEX: BPA) today announced that Stephen M. Simes, president and CEO of BioSante will present a corporate overview and update at the Arch Investment Conference on September 6, 2007 at 1:00 p.m. local time at the Warwick Hotel in New York City.
A live audio webcast of BioSante’s presentation at the Arch conference can be accessed on the internet by visiting www.biosantepharma.com. An archive of this presentation will be available at the same address.
This conference features companies presenting to a diverse group of investors, portfolio managers and analysts interested in the biotechnology and pharmaceutical sectors as well as other industries. compensation expense.
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bio-identical estradiol and testosterone. BioSante’s lead products include Elestrin™ (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante’s licensee, and LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD).
Also in development is Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and biodefense vaccines for toxins such as anthrax, as well as a system for delivering drugs via alternative routes of administration and for aesthetic medicine. Additional information is available online at www.biosantepharma.com.
For more information please contact:
Harris D. McKinney, Inc.